|
시장보고서
상품코드
2056358
의약품 정밀화학 시장 보고서 : 유형, 제품 유형, 규모, 용도, 지역별(2026-2034년)Pharmaceutical Fine Chemicals Market Report by Type, Product, Size, Application, and Region 2026-2034 |
||||||
세계의 의약품 정밀화학 시장 규모는 2025년에 1,571억 달러에 이르렀습니다. 향후는 2034년까지 시장 규모가 2,506억 달러에 이르고, 2026-2034년에 CAGR 5.17%를 나타낼 것으로 예측했습니다.
의약품 정밀화학이란, 고가이며 한정된 수량으로 생산되는 순수하고 복잡한 화학 물질군을 말합니다. 이들은 다단계 배치식 생명공학 공정을 이용하여 다목적 플랜트에서 생산됩니다. 특수 화학 물질과 달리, 이러한 물질들은 명확한 기능적 특성이나 특정 분자적 특성에 기초하여 정밀하게 정제됩니다. 정제된 정밀 화학 물질은 스테아린산 마그네슘이나 젤라틴 등 다양한 의약품 및 화학제품 제조 과정에서 주요 원료, 안정제, 용매로 사용됩니다. 현재, 이러한 제품들은 자체 개발 제품 및 타사 제품의 형태로 시중에 판매되고 있습니다.
의약품 정밀화학 시장 동향 :
부정맥, 뇌졸중, 암, 관상동맥 질환 등, 특히 고령층에서 다양한 신경계 및 심혈관 질환의 유병률 증가는 의약품 정밀화학 시장의 성장을 이끄는 주요 요인 중 하나입니다. 이에 따라 신종 코로나바이러스 감염증(COVID-19) 및 기타 질병에 대응하기 위한 신규 백신, 의약품, 의료용 약제의 도입을 위해 각국 정부 기관이 적극적으로 추진하는 노력들이 의료 분야에서의 이러한 약제 보급을 더욱 촉진하고 있습니다. 이것이 시장에서의 추가적인 성장 요인이 되고 있습니다.
또한, 품질 기준을 충족하면서 의약품 제조 원료로 의약품 정밀화학 물질을 활용하기 위한 다양한 지침이 시행되고 있는 점도 시장 성장에 기여하고 있습니다. 기타에도 제약 업계의 급속한 성장, 연구개발(R&D) 활동에 대한 투자 증가, 그리고 다양한 질환과 이용 가능한 치료 옵션에 대한 소비자의 인식 제고와 같은 요인들이 맞물려 전 세계 시장에서 밝은 전망을 제시하고 있습니다.
본 보고서에서 다룬 주요 질문
- 세계 의약품 정밀화학 시장 규모는 어느 정도인가?
- 2026년부터 2034년까지 전 세계 의약품 정밀화학 시장의 예상 성장률은 어느 정도인가?
- 세계 의약품 정밀화학 시장을 주도하는 주요 요인은?
- COVID-19는 전 세계 의약품 정밀화학 시장에 어떤 영향을 미쳤는가?
- 세계 의약품 정밀화학 시장은 유형별로 어떻게 분류되는가?
- 세계 의약품 정밀화학 시장은 제품별로 어떻게 분류되는가?
- 세계 의약품 정밀화학 시장은 규모별로 어떻게 세분화되는가?
- 세계 의약품 정밀화학 시장의 주요 지역은?
- 세계 의약품 정밀화학 시장에서 주요 업체는?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 의약품 정밀화학 시장
제6장 시장 분석 : 유형별
제7장 시장 분석 : 제품별
제8장 시장 분석 : 사이즈별
제9장 시장 분석 : 용도별
제10장 시장 분석 : 지역별
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
제14장 가격 분석
제15장 경쟁 구도
JHSThe global pharmaceutical fine chemicals market size reached USD 157.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 250.6 Billion by 2034, exhibiting a growth rate (CAGR) of 5.17% during 2026-2034.
Fine chemicals refer to a set of pure and complex chemicals that are manufactured in limited quantities at higher prices. They are produced in multipurpose plants with the support of a multistep batch biotechnological method. Unlike specialty chemicals, these substances are accumulated precisely based on their distinct functional characteristics and specific molecular properties. After collection, fine chemicals are used as key agents, stabilizers, and solvents for producing several pharmaceutical chemical products, including magnesium stearate and gelatin. At present, they are commercially available in proprietary and non-proprietary variants.
Pharmaceutical Fine Chemicals Market Trends:
The increasing prevalence of various neurological and cardiovascular diseases, including arrhythmias, stroke, cancer, and coronary artery ailments, especially amongst the geriatric population, is one of the prime factors driving the pharmaceutical fine chemical market toward growth. In line with this, favorable initiatives undertaken by the government bodies of several nations for introducing novel vaccines, drugs, and pharmaceutical medications for retaliating against coronavirus diseases (COVID-19) and several other disorders is further facilitating the widespread adoption of these medications in the healthcare sector. This, in turn, is acting as another growth-inducing factor in the market.
Additionally, enforcement of different guidelines for utilizing pharmaceutical fine chemicals as raw materials to manufacture medicines, while meeting the quality standards is contributing to the market growth. Other factors, such as significant expansion in the pharmaceutical industry, increasing investments in the research and development (R&D) activities, and the growing consumer awareness regarding numerous disorders and the available medication options, are creating a positive outlook for the market across the globe.
Key Market Segmentation:
The research provides an analysis of the key trends in each sub-segment of the global pharmaceutical fine chemicals market report, along with forecasts at the global, regional and country level from 2026-2034. Our report has categorized the market based on type, product, size and application.
Breakup by Type:
- Proprietary
- Non-proprietar.
Breakup by Product:
- Active Ingredients
- Basic Building Blocks
- Advanced Intermediate.
Breakup by Size:
- Big Molecules
- Small Molecule.
Breakup by Application:
- Cardiovascular
- Neurological
- Oncological
- Respiratory
- Gastrointestinal
- Musculoskeletal
- Other.
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Afric.
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being BASF SE, Borregaard ASA, CHEMADA Industries Ltd. (Turpaz), Denisco Chemicals Pvt Ltd, Dupont De Nemours Inc., Eastman Chemical Company, Evonik Industries AG, Koninklijke DSM N.V., Lonza Group AG, Solvay S.A., Syntor Fine Chemicals Ltd. (Aceto Corporation) and W. R. Grace and Co. (Standard Industries Inc.).
Key Questions Answered in This Report
- How big is the global pharmaceutical fine chemicals market?
- What is the expected growth rate of the global pharmaceutical fine chemicals market during 2026-2034?
- What are the key factors driving the global pharmaceutical fine chemicals market?
- What has been the impact of COVID-19 on the global pharmaceutical fine chemicals market?
- What is the breakup of the global pharmaceutical fine chemicals market based on the type?
- What is the breakup of the global pharmaceutical fine chemicals market based on the product?
- What is the breakup of the global pharmaceutical fine chemicals market based on the size?
- What are the key regions in the global pharmaceutical fine chemicals market?
- Who are the key players/companies in the global pharmaceutical fine chemicals market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Pharmaceutical Fine Chemicals Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Proprietary
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Non-proprietary
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Product
- 7.1 Active Ingredients
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Basic Building Blocks
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Advanced Intermediates
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Size
- 8.1 Big Molecules
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Small Molecules
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by Application
- 9.1 Cardiovascular
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Neurological
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Oncological
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Respiratory
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
- 9.5 Gastrointestinal
- 9.5.1 Market Trends
- 9.5.2 Market Forecast
- 9.6 Musculoskeletal
- 9.6.1 Market Trends
- 9.6.2 Market Forecast
- 9.7 Others
- 9.7.1 Market Trends
- 9.7.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 BASF SE
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Borregaard ASA
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.3 CHEMADA Industries Ltd. (Turpaz)
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.4 Denisco Chemicals Pvt Ltd
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.5 Dupont De Nemours Inc.
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 Eastman Chemical Company
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 Evonik Industries AG
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 Koninklijke DSM N.V.
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 Lonza Group AG
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Solvay S.A.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Syntor Fine Chemicals Ltd. (Aceto Corporation)
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.12 W. R. Grace and Co. (Standard Industries Inc.)
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
- 15.3.12.3 SWOT Analysis
- 15.3.1 BASF SE
